Emergent BioSolutions Inc (EBS)

38.34
NYSE : Health Care
Prev Close 37.67
Day Low/High 37.58 / 38.47
52 Wk Low/High 24.47 / 38.74
Avg Volume 271.10K
Exchange NYSE
Shares Outstanding 41.21M
Market Cap 1.55B
EPS 1.30
P/E Ratio 25.80
Div & Yield N.A. (N.A)

Latest News

Emergent BioSolutions Awarded $63 Million BARDA Contract To Develop Treatment For Cyanide Exposure

Biotech movers: Ionis Drops After GSK Bows Out of Partnership
Emergent BioSolutions Reports Second Quarter And Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance

Emergent BioSolutions Reports Second Quarter And Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance

Emergent BioSolutions Awarded $23 Million To Develop Novel Multi-Drug Auto-Injector For U.S. Department Of Defense

Emergent BioSolutions Awarded $23 Million To Develop Novel Multi-Drug Auto-Injector For U.S. Department Of Defense

Emergent BioSolutions Secures Exclusive Worldwide Rights To Valneva's Zika Vaccine Technology

Emergent BioSolutions Secures Exclusive Worldwide Rights To Valneva's Zika Vaccine Technology

Emergent BioSolutions To Release Second Quarter 2017 Financial Results And Conduct A Conference Call On August 3, 2017

Emergent BioSolutions To Release Second Quarter 2017 Financial Results And Conduct A Conference Call On August 3, 2017

Emergent BioSolutions To Acquire Raxibacumab, An FDA-Approved Anthrax Monoclonal Antibody, From GSK

Emergent BioSolutions To Acquire Raxibacumab, An FDA-Approved Anthrax Monoclonal Antibody, From GSK

Emergent BioSolutions To Acquire ACAM2000® Business From Sanofi

Emergent BioSolutions To Acquire ACAM2000® Business From Sanofi

Emergent BioSolutions To Hold Annual Meeting Of Stockholders Thursday May 25, 2017 At 9:00 AM EDT; Webcast Will Be Available

Emergent BioSolutions Unveils Its Expanded Center For Innovation In Advanced Development And Manufacturing In Baltimore

Emergent BioSolutions To Unveil Its Expanded Center For Innovation In Advanced Development And Manufacturing Supported Through Public-Private Partnership With BARDA

112,000-Square-Foot Baltimore Facility Is Designed to Enable Surge Manufacturing of Medical Countermeasures to Address Urgent Public Health Threats

Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance

Emergent BioSolutions To Release First Quarter 2017 Financial Results And Conduct A Conference Call On May 4, 2017

Emergent BioSolutions Signs $53 Million Modification To BARDA Contract For The Manufacture Of Botulism Antitoxin

Emergent BioSolutions Awarded $100 Million BARDA Contract For BioThrax Deliveries To The Strategic National Stockpile

Emergent BioSolutions Reports Fourth Quarter And Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance And Provides 2020 Goals

Emergent BioSolutions Receives BARDA Task Order Valued At Up To $30.5 Million To Develop Viral Hemorrhagic Fever Therapeutics

Emergent BioSolutions To Release Fourth Quarter And Full Year 2016 Financial Results And Conduct A Conference Call On February 23, 2017

Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study To Evaluate Broad-Spectrum Antiviral UV-4B For Dengue

Emergent BioSolutions Receives German Federal Ministry Of Health Approval Of Building 55 For Large-Scale Manufacturing Of BioThrax

Emergent BioSolutions Announces Preliminary 2016 Financial Results And Provides 2017 Financial Outlook

Emergent BioSolutions Announces Preliminary 2016 Financial Results And Provides 2017 Financial Outlook

Emergent BioSolutions To Participate In First Quarter 2017 Investor Conferences

Emergent BioSolutions To Participate In First Quarter 2017 Investor Conferences

Emergent BioSolutions Receives Health Canada Approval For Botulism Antitoxin

Emergent BioSolutions Receives Health Canada Approval For Botulism Antitoxin

Emergent BioSolutions To Support HHS Anthrax Preparedness Strategy With Up To $1 Billion In BioThrax Deliveries To The Strategic National Stockpile

Emergent BioSolutions To Support HHS Anthrax Preparedness Strategy With Up To $1 Billion In BioThrax Deliveries To The Strategic National Stockpile

Dr. Kathryn C. Zoon Appointed To Emergent BioSolutions Board Of Directors

Dr. Kathryn C. Zoon Appointed To Emergent BioSolutions Board Of Directors

Emergent BioSolutions Reports Third Quarter And Nine Months 2016 Financial Results

Emergent BioSolutions Reports Third Quarter And Nine Months 2016 Financial Results

Emergent BioSolutions To Release Third Quarter 2016 Financial Results And Conduct A Conference Call On November 7, 2016

Emergent BioSolutions To Release Third Quarter 2016 Financial Results And Conduct A Conference Call On November 7, 2016

Emergent BioSolutions Provides Update On Status Of BioThrax Procurement Contract And Discussions With CDC

Emergent BioSolutions Provides Update On Status Of BioThrax Procurement Contract And Discussions With CDC

Emergent BioSolutions Awarded BARDA Contract For Advanced Development And Delivery Of NuThrax, A Next Generation Anthrax Vaccine, Valued At Up To $1.6 Billion

Emergent BioSolutions Awarded BARDA Contract For Advanced Development And Delivery Of NuThrax, A Next Generation Anthrax Vaccine, Valued At Up To $1.6 Billion

EMERGENT 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors Of Deadline In Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS

EMERGENT 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors Of Deadline In Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.

Load More
Quant Rating on 4:02 PM EDT 9/22/2017

B

(Buy)

From Our Partners

Emergent Bio nabs $63M BARDA contract for cyanide poisoning antidote
SeekingAlpha

Wells says Emergent contract with BARDA 'good news' that expands portfolio
The Fly

Emergent BioSolutions (EBS) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
SeekingAlpha

Emergent BioSolutions misses by $0.13, misses on revenue
SeekingAlpha

Notable earnings after Thursday’s close
SeekingAlpha

Emergent Bio nabs $23M DoD contract to develop multidrug auto-injector
SeekingAlpha

Emergent Bio buys anthrax biologic raxibacumab from Glaxo for up to $96M
SeekingAlpha

Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
The Fly

Emergent BioSolutions buys smallpox vaccine assets from Sanofi unit for up to $125M
SeekingAlpha

Wall Street Breakfast: Tesla Gears Up For Model 3
SeekingAlpha

Ebola outbreak over in Congo
SeekingAlpha

Emergent BioSolutions: A Very Attractive Risk/Reward Biodefense Play
SeekingAlpha

Emergent BioSolutions (EBS) Presents At Three Part Advisors 2017 East Coast IDEAS Investor Conference - Slideshow
SeekingAlpha

Congo reports rise in Ebola cases, now 29
SeekingAlpha

Emergent BioSolutions misses by $0.07, beats on revenue
SeekingAlpha
TheStreet Quant Rating: B (Buy)

Get the (EBS)
Report Here

Watchlist

Trending
Why This Former Tech CEO Thinks One of the Biggest Business Risks Is Fear
Tim Cook Says iPhone 8, Apple Watch 3 Already Sold Out in Some Locations
Kraft Heinz's New CFO Is Just 29
Barack Obama Is Now Among 10 Highest-Paid Public Speakers
The 12 Most Ridiculous Kitchen Appliances You Can Buy From Amazon